Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Sanofi Asks Trade Agency to Block Spectrum’s Rolontis From U.S.

Dec. 20, 2021, 11:49 PM

Sanofi’s Bioverativ filed a U.S. trade complaint seeking to block imports of Spectrum Pharmaceuticals’ proposed Rolontis, a drug used to treat a condition caused by chemotherapy that leaves patients more susceptible to infections.

  • Bioverativ and Genzyme claim Spectrum and its South Korean manufacturer, Hanmi Pharmaceutical, infringe a patent that expires in 2028 for what the Sanofi units called an “innovative platform technology” which can prolong the half-lives of biologic-based treatments
  • The technology has “wide-ranging applications” and is used by Sanofi in Eloctate and Alprolix, which are used for patients with rare blood disorders, according to the complaint ...

To read the full article log in.

Learn more about a Bloomberg Law subscription